DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Disposition of Intravenous Ketorolac

Information source: Universitaire Ziekenhuizen Leuven
Information obtained from ClinicalTrials.gov on December 08, 2011
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Postoperative Pain

Intervention: Ketorolac Tromethamine (Drug)

Phase: Phase 4

Status: Not yet recruiting

Sponsored by: Universitaire Ziekenhuizen Leuven

Official(s) and/or principal investigator(s):
Karel Allegaert, MD PhD, Principal Investigator, Affiliation: University Hospitals Leuven

Overall contact:
Allegaert Karel, MD PhD, Phone: 0032-16-345506, Email: karel.allegaert@uz.kuleuven.ac.be

Summary

The purpose of this study is:

- to document ketorolac disposition (concentration/time profile, protein binding,

metabolism) and its covariates following intravenous (iv) administration of ketorolac right after caesarean section and to compare those observations (n=32) with non-pregnant state (n=8) (intra-subject PK comparison)

- to document biochemical tolerance of ketorolac

- to evaluate if optimalisation of ketorolac dose regimen during pregnancy and labor are

appropriated and needed

- to quantify the neonatal exposure to ketorolac through excretion in the breast milk

Clinical Details

Official title: Disposition of Intravenous Ketorolac After Cesarean Section

Study design: Endpoint Classification: Pharmacokinetics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: ketorolac disposition following intravenous administration right after caesarean section

Secondary outcome: optimalisation of ketorolac dose regimen during pregnancy and labor

Detailed description: Prospective, single-center, open label study on the pharmacokinetics of intravenous (iv) ketorolac administration in pregnant women right after caesarean section. Patients will be included after signed informed consent. Ketorolac has been selected for this study as it is routinely administered for postoperative pain relief. At this stage, we only have the intention to document ketorolac pharmacokinetics and metabolism based on the dosing regimen as currently used in the clinical setting, and therefore will not interfere with either clinical indications, nor with dosing as prescribed by the attending physician. This drug is routinely administered (30 mg q8h) after caesarean section.

Drug administration and collection of samples will be obtained to the current clinical and nursing standard procedures. After dilution in 50-100 ml bag of normal saline drug will be administered after caesarean section by iv bolus, through a peripherally inserted venous catheter, 30 mg, 3 times in one day. The intended duration of administration is 5-10 minutes.

Blood samples will be collected (in heparinised tubes) according to following schedule: 1, 2, 3, 4, 6 and 8 hours after iv administration, through a second peripherally inserted venous catheter dedicated for blood sampling only. Blood samples will be centrifuged

immediately after collection and subsequently stored at - 20 °C until analysis. Urine samples

will also be collected, before drug administration in the first 8 hours after the first drug administration, through a bladder catheter in patients in whom a bladder catheter is available for clinical indications.

In a subgroup of former patients (n=8), we plan to repeat this procedure 6-12 weeks after delivery (for intra-subject PK comparison). However, only a single iv ketorolac dose will be administered, and sampling will be limited to 6 samples up to 8 h following start of iv administration. A population pharmacokinetics approach will be used, hereby comparing the data on PK already reported in adults and the newly collected data following pregnancy.

Eligibility

Minimum age: 18 Years. Maximum age: 50 Years. Gender(s): Female.

Criteria:

Inclusion Criteria:

- signed informed written consent

- pregnant women to whom ketorolac is administered by intravenous route for clinical

indications

- preferable availability for revision in 6-12 weeks after delivery (around routine

post-delivery check-up).

Exclusion Criteria:

- withdrawal of informed written consent

- known NSAID's intolerance

Locations and Contacts

Allegaert Karel, MD PhD, Phone: 0032-16-345506, Email: karel.allegaert@uz.kuleuven.ac.be

University Hospitals Leuven, Leuven 3000, Belgium
Additional Information

Starting date: July 2011
Last updated: February 7, 2011

Page last updated: December 08, 2011

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012